Circulating suPAR in two cohorts of primary FSGS. - Wikidata - thesis-toulmin - TriplyDB

Circulating suPAR in two cohorts of primary FSGS.

Circulating suPAR in two cohorts of primary FSGS.

http://www.wikidata.org/entity/Q36426091

about

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View Long-term Outcomes of Childhood Onset Nephrotic Syndrome FSGS: Diagnosis and Diagnostic Work-Up Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates FSGS Recurrence in Adults after Renal Transplantation A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues Podocyte pathology and nephropathy - sphingolipids in glomerular diseases Glomerular diseases: FSGS.Pathogenesis of Focal Segmental Glomerulosclerosis LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy suPAR and Team Nephrology Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Complement Activation in Patients with Focal Segmental Glomerulosclerosis.Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.Soluble Urokinase Receptor and Chronic Kidney Disease.Primary glomerulonephritis: A review of important recent discoveries.Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study Circulating permeability factor suPAR: from concept to discovery to clinic.Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report Has the circulating permeability factor in primary FSGS been found?Rituximab in idiopathic nephrotic syndrome: does it make sense?Novel biomarkers in glomerular disease.

P2860

Q26738374-840845F7-B061-49F1-96C5-2E50EAF95F18 Q26744025-9FB85025-D544-46F8-B3DD-6C4D0B7C0E80 Q26744558-1A7445D5-4EFA-4997-A266-FA5BA3129B30 Q26747221-4BDB6424-9867-4842-AAE7-D5B88FFB1DBF Q26752840-F2C12A83-5020-4B8A-8E4C-EF15F06FAB7B Q26776389-547565B5-437D-490E-BEEB-ADFFEE589FAD Q26852463-2322A1CC-CD13-4091-81E2-8DDF4042DB29 Q27687257-FF0FA0C9-512D-4D47-A7D9-804719F096F7 Q28067299-CA1A14DC-B9B5-4691-A0C2-A4194FBFC683 Q28544395-617A1B1C-AA0F-400B-8B34-39436D11D005 Q33632316-35B9C3D3-3975-45FE-8EDA-F8107C9C867B Q33634270-CD15632C-5C8B-4D2B-93B4-1AE9C0320D01 Q33783271-837A056A-56DA-481F-A543-5380C3B5C579 Q33974535-059CBF6C-921D-46B2-83CB-CC91D2FE1F9B Q33993597-B966A2DA-C32F-4A72-8D28-4D4B14826A07 Q34060349-885BC5FF-93AA-469B-9FFC-4037988C965E Q34231973-87ACEC12-416D-4A75-89D7-790375DD1922 Q34455143-943111DA-FE1C-45AF-AB22-AFD87BF3DA35 Q34760971-B6EECCBE-C12F-4F80-9D13-F7BAB5484F85 Q34787771-FE612509-EA4C-4843-8A9D-763A7A952804 Q34787780-E4477ABA-1129-44F5-9438-3B7779D3877D Q35132279-26D885D2-C199-428B-9881-D0203884920D Q35144440-CE8DDF33-0519-424A-A0BD-3F663D8464B2 Q35379384-9C7B37E9-D69D-418C-8C55-2D5898426317 Q35658566-D5AD7E57-9D73-43F8-8153-67DA88F0D75E Q35704498-E3D1F241-5820-4659-BECB-B61ED84E642B Q35763276-DAF3EDAF-1DE5-4954-AAC9-077B61087C05 Q35779133-C512F155-CABB-42D3-B149-C43799CBBB76 Q36003160-3A6E0480-7669-42C9-80C1-38A3565BF11D Q36429637-613CAA4A-1929-4C12-B8A4-EC79897A9E2C Q36465902-9D86AF59-629B-4F74-8F3D-29BD36976635 Q36549551-8818BA76-4298-4D84-993A-9D07F2D98DC8 Q36908288-B87F4CB1-6C13-4FD2-B68A-66CEB585E3BC Q36987307-D2B2C44B-262C-420C-9D3F-1D0FCEF17AB2 Q36992978-7A1C32B7-AC66-4241-9C22-A1EA94787C83 Q37026094-E7BA285F-567B-4C8D-BB13-43DA15719821 Q37065608-2411EE49-F234-4FA9-91FD-24811FEA0FE4 Q37070274-F069C7EF-AD7E-4EFB-BBA5-C5859EA9A6D3 Q37375752-E734727C-EAB5-4F68-ABF1-0E089F09F3B9 Q37658483-4AD64D51-E990-4018-A8C3-A40315058D04

P2860

Circulating suPAR in two cohorts of primary FSGS.

http://www.wikidata.org/entity/Q36426091

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Circulating suPAR in two cohorts of primary FSGS.

@ast

Circulating suPAR in two cohorts of primary FSGS.

@en

type

label

Circulating suPAR in two cohorts of primary FSGS.

@ast

Circulating suPAR in two cohorts of primary FSGS.

@en

prefLabel

Circulating suPAR in two cohorts of primary FSGS.

@ast

Circulating suPAR in two cohorts of primary FSGS.

@en

P1433

Q36426091-C561DA18-4DED-4287-A3B3-2A48C5C5D01D

P1476

Q36426091-E8FB4751-19A0-455C-AC2C-A7F0E2E8A199

P2093

Q36426091-1762016C-603F-4475-B4D8-E7922508843A

Q36426091-1FC63B9D-51E1-4E3D-87EE-51464BA4555A

Q36426091-248F2E3D-E17D-42E6-ABBA-DA9932BB694E

Q36426091-25CED0D8-9E3D-48A2-A8F0-35D8B32CDFD4

Q36426091-3075E230-FD7C-46EA-AFF7-740EA8A7F7AE

Q36426091-5AF6D04A-4DC6-44B5-8BED-BF56585C568A

Q36426091-5FDE922B-65A0-44ED-B3BC-1C45A12A694A

Q36426091-6CE13B29-1B30-4E2C-81E7-8571B3AFD693

Q36426091-72A19633-4278-4DB5-9D43-27AD08541A7D

Q36426091-8AC5CA5D-34F7-456D-B242-67578BC7663B

P2860

Q36426091-0D15A9C0-794C-4863-A19B-C3E2A446A15C

Q36426091-13A8E776-522D-4A2A-8145-6527E84750B8

Q36426091-16A6876A-80FC-45BF-BB8A-AAD611DC9C61

Q36426091-20D9A0CC-1424-4548-A366-973D1E8FE18C

Q36426091-30E13C5B-FE7D-4CAA-A04E-6897C8E91BC8

Q36426091-3B2786C7-018D-4A38-B2E2-AF557420BEF9

Q36426091-3FB954CC-65AA-4DEE-8F26-C69DB2FA9402

Q36426091-40792634-7EC0-4C9C-8B34-AD5A5F5C27BF

Q36426091-54D8B334-6DE7-4639-85A3-79EF0F031C85

Q36426091-5F728189-4D0A-407C-9DB8-EDA99182A9B3

P304

Q36426091-07EE6E71-8844-4A4A-A0B9-CE8924E62062

P31

Q36426091-DF255605-A5AB-42E0-965F-27BB70171292

P356

Q36426091-2B383FA1-0D84-4B9A-97D9-6039766812EB

P433

Q36426091-4FCBCF60-DFEE-420B-8CE1-C8F87FCD7458

P478

Q36426091-7567C5E2-7C98-4DAD-8AC7-BDD3C0F973A5

P577

Q36426091-05A2DEA4-185F-418B-88AD-F9CD2C9FDF8B

P698

Q36426091-7587F0B0-73E3-4D5B-AC74-A2E8ED7FB084

P932

Q36426091-03C96A08-8F1C-4E55-B15F-5C0F3AF03A86

P356

P1433

Journal of the American Society of Nephrology

P1476

Circulating suPAR in two cohorts of primary FSGS.

@en

P2093

Aaron L Friedman

http://www.w3.org/2001/XMLSchema#string

Agnes Trautmann

http://www.w3.org/2001/XMLSchema#string

Ali Anarat

http://www.w3.org/2001/XMLSchema#string

Changli Wei

http://www.w3.org/2001/XMLSchema#string

Chuanhui Dong

http://www.w3.org/2001/XMLSchema#string

Dagmar-Christiane Fischer

http://www.w3.org/2001/XMLSchema#string

Debbie S Gipson

http://www.w3.org/2001/XMLSchema#string

Dieter Haffner

http://www.w3.org/2001/XMLSchema#string

Fatih Ozaltin

http://www.w3.org/2001/XMLSchema#string

Franz Schaefer

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Management of focal segmental glomerulosclerosis: evidence-based recommendations.

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.

Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome.

Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

P304

2051-2059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012030302

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23138488

http://www.w3.org/2001/XMLSchema#string

P932

3507361

http://www.w3.org/2001/XMLSchema#string